Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

How to launch a drug in a pandemic with Immunomedics

During the ongoing Covid-19 pandemic, the FDA has continued in its normal role of approving safe and effective drugs. But how do pharma companies go about bringing a new drug to market during the pandemic? Immunomedics’ chief commercial officer Brendan Delaney explains how his company has successfully facilitated the treatment of US patients with its first ever drug, Trodelvy, which was approved at the end of April.

Close
Close
Close

Go Top